Today: 8 June 2026
Browse Category

NASDAQ:BNTX 22 June 2025 - 7 January 2026

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer launched a U.S. dollar bond sale aiming to raise at least $5 billion to help fund its recent Metsera acquisition, which closed Nov. 13 for up to $10 billion. The offering may include up to seven tranches, with early talks on a 40-year note at about 125 basis points over Treasuries. Pfizer shares traded near $25.11 as of 16:12 UTC, little changed on the day.
18 November 2025
·····
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol Myers Squibb priced €5 billion in senior notes across five tranches, with closing expected Nov. 10; proceeds will fund a debt tender offer running through Dec. 3. The company agreed to a $239 million settlement in a Celgene class action, pending court approval. BioNTech raised its 2025 revenue outlook after receiving payments from a new BMS alliance. FDA approved a generic for Sprycel on Nov. 7.
9 November 2025
··
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

China researchers reported a hydrogel “smart” wound dressing that closed 90% of diabetic ulcers in mice within 12 days by delivering microRNA vesicles. The FDA approved Boehringer Ingelheim’s Hernexeos for advanced non-squamous NSCLC, with 75% of treated patients seeing tumors shrink or disappear. U.S. IV saline shortages ended as Baxter’s North Carolina plant resumed production after hurricane damage.
10 August 2025
······
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer and BioNTech co-developed Comirnaty, the first FDA-approved mRNA COVID-19 vaccine. Roche leads in oncology and diagnostics, while Moderna advanced mRNA vaccines for COVID-19 and other diseases. Illumina dominates DNA sequencing, and CRISPR Therapeutics develops gene-editing therapies for sickle cell disease.
22 June 2025
···········

Stock Market Today

  • Broadcom Stock Hits Historic Buy Opportunity Amid AI Growth Forecast
    June 8, 2026, 5:11 PM EDT. Broadcom (NASDAQ:AVGO) reported strong Q2 fiscal 2026 results with revenue up 48% year-over-year to $22.2 billion and AI semiconductor revenue soaring 143% to $10.8 billion. Despite this, shares dropped 20% from recent highs, trading near $398. Mizuho analysts forecast a surge in tensor processing unit (TPU) sales, projecting over 35 million units by 2028, driven by hyperscaler demand and OpenAI's expansion. This could generate $300 billion in revenue from Google-related TPU work alone. Broadcom's AI revenue is expected to climb from $56 billion in FY 2026 to $170 billion in FY 2028. The pullback is seen as a significant buying opportunity given the firm's strong AI semiconductor position and custom silicon momentum.

Latest articles

Social Security Payments Land This Week—June 10 Recipients

Social Security Payments Land This Week—June 10 Recipients

8 June 2026
Social Security’s retirement trust fund could force a 24% benefit cut by 2032, slashing average monthly payments by about $500 for retirees, according to the Committee for a Responsible Federal Budget, as the official trustees project full benefits only until 2033 and continuing income covering just 77% thereafter.
IonQ Jumps as Quantum IPO Rush Sets Wall Street Benchmark

IonQ Jumps as Quantum IPO Rush Sets Wall Street Benchmark

8 June 2026
IonQ surged 10.5% to $62.77, outpacing quantum peers after Quantinuum’s $1.68 billion Nasdaq IPO gave investors a new benchmark for trapped-ion quantum stocks; IonQ’s rally follows its May guidance raise and soaring revenue, but losses and a long commercialization timeline remain key risks.
Snap Shares Climb as Debt Markets Send Signal

Snap Drops Again as Wall Street Stays Wary

8 June 2026
Snap plunged 2.1% to $5.64, underperforming a tech rebound, as investors weighed improved cash flow and a recent S&P credit upgrade against ongoing ad-market pressure, cost cuts, and spending on Specs; the stock’s weakness stood out as peers like Pinterest gained, highlighting market doubts about Snap’s ability to sustain growth amid tough competition and uncertain ad budgets.
Dow Drops After Hours, AI Rally Sidesteps Blue Chips

Dow Drops After Hours, AI Rally Sidesteps Blue Chips

8 June 2026
The Dow Jones fell 104.70 points, or 0.21%, to 50,762.08 as tech and chip stocks rebounded sharply, with the Philadelphia SE Semiconductor Index up 6.2% after Friday’s $1 trillion selloff; Apple dropped 1.4% despite its AI event, and investors now await Wednesday’s inflation data and Middle East energy risks as the next key tests for the market’s fragile rebound.
Go toTop